drugset / Trial / NCT03682497

Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

NCT03682497

Phase 1 Terminated 68 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium \[sK+\] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of ≥40 and ≤70 mL/min/1.73m2.

Timeline

Start
2018-11-01
Primary completion
2020-03-31
Completion
2020-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Spironolactone Small molecule Oral
Subject balcinrenone Small molecule Oral

Indications